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ABSTRACT: Background. Concurrent chemoradiotherapy (concurrent
CRT) to treat head and neck cancer is associated with significant reduc-
tions of weight, mobility, and quality of life (QOL). An intervention focus-
ing on functional exercise may attenuate these losses.
Methods. We allocated patients to a 14-week functional resistance and
walking program designed to maintain physical activity during cancer
treatment (MPACT group; n 5 11), or to usual care (control group; n 5
9). Outcomes were assessed at baseline, and 7 and 14 weeks.
Results. Compared to controls, the MPACT participants had attenuated
decline or improvement in several strength, mobility, physical activity, diet,
and QOL endpoints. These trends were statistically significant (p < .05) in
knee strength, mental health, head and neck QOL, and barriers to exercise.
Conclusion. In this pilot study of patients with head and neck cancer
undergoing concurrent CRT, MPACT training was feasible and main-
tained or improved function and QOL, thereby providing the basis for
larger future interventions with longer follow-up. VC 2015 Wiley Periodi-
cals, Inc. Head Neck 38: E1086–E1096, 2016
KEY WORDS: head and neck cancer, physical activity, quality of life,
radiation therapy, functional mobility
INTRODUCTION
Head and neck cancer affects more than 52,000 Ameri-
cans yearly, accounting for 5% of cancers worldwide, and
with a 5-year overall survival of 57%.1 Historically, most
head and neck cancer occurs in older men with a history
of significant tobacco and alcohol exposure. However,
recent evidence suggests a shift in the epidemiology of
head and neck cancer with a rise in the incidence of
human papillomavirus (HPV)-positive disease among non-
smokers who present at an earlier age. Although HPV-
positive cancers are associated with more extensive nodal
disease, they generally respond better to treatment and are
associated with improved overall survival resulting in an
ever-growing number of cancer survivors.2,3 Given the
higher rates of tumor response and better prognosis in
HPV-positive cancers, the focus in head and neck cancer
research has changed from attempting to increase tumor
response rates to identifying strategies that can decrease
long-term treatment-related effects.
Treatment of head and neck cancer with concurrent
chemoradiotherapy (CRT) with curative intent may cause
side effects leading to deterioration of long-term quality
of life (QOL) and disability that persists years after treat-
ment. Head and neck cancer and its treatment can
severely impact the ability to eat, speech, physical
appearance, and emotional well-being.4,5 These side
effects may worsen body image, self-esteem, and social
interactions in patients with head and neck cancer.6,7 To
improve the QOL of patients with cancer, cost-effective
clinical paradigms that promote overall well-being,
including lifestyle changes, are essential.8
Patients with head and neck cancer often experience
significant unintentional weight loss despite adequate
nutritional support.9,10 A large percentage of this weight
loss is in lean body (muscle) mass.8,11 Muscle mass loss
is associated with disability, deficits in functional mobil-
ity, and a decrease in physical activity level, as well as
reduced QOL and worse overall patient prognosis.12–18
Moreover, muscle mass loss occurs despite aggressive
nutritional interventions to maintain body weight,10 and
dietary interventions alone increase fat mass with no
effect on lean body mass.17 Patients with head and neck
cancer are generally less active than other patients with
cancer, suggesting that sedentary behavior may worsen
muscle mass loss through muscle disuse and decondition-
ing.12 Exercise and a focus on physical activity may
counteract this unintentional weight loss, muscle mass
loss, and attenuate the decline in QOL.
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Exercise training has been demonstrated to improve
strength, function, and QOL in patients undergoing
treatment for cancers other than head and neck cancer,
including breast, prostate, lung, and hematologic malignan-
cies.19–28 However, many of those studies have focused on
patients with breast and prostate cancer, who often are in
better health at baseline, whose definitive treatment may
not be as debilitating, and who do not suffer as much mus-
cle mass loss compared with patients with head and neck
cancer. At diagnosis, patients with head and neck cancer
present with low baseline physical activity levels that
remain low after treatment, with more than half of patients
unable to return to work after treatment.18,29 Finally,
whereas most studies have focused on exercise in cancer
treatment survivors, initiating exercise interventions during
definitive treatment may be more optimal,21–23,25,28 thereby
providing the potential to limit treatment side effects and
provide techniques that can accelerate recovery.
We conducted a pilot controlled trial to assess the fea-
sibility and efficacy of a functional resistance and walk-
ing exercise intervention (maintaining physical activity
during cancer treatment [MPACT]) both during concur-
rent CRT and in short-term follow-up after treatment.
Our primary purposes were to assess the benefits of
MPACT on muscle strength, functional mobility, and
self-reported QOL in patients with head and neck can-
cer. Our hypothesis was that, compared to usual care
controls, participants allocated to the MPACT interven-
tion would exhibit less concurrent CRT-induced decline
and accelerated post-concurrent CRT recovery in a num-
ber of key measures, including muscle strength, func-
tional mobility, and QOL. Secondary aims were to
assess the benefit of MPACT on other key endpoints,
including body mass index (BMI), lean body mass, diet,
activity (both self-reported and objectively measured),
sleep, concurrent CRT toxicity, and barriers to exercise.
Data from this study can be used to guide a more exten-
sive intervention with longer-term follow-up to demon-
strate not just attenuation of the concurrent CRT effect,




Eligibility criteria included patients 40 years or older
with American Joint Committee on Cancer stage II to IV
head and neck squamous cell carcinoma who were begin-
ning first-line concurrent CRT without surgery and who
were capable of understanding and adhering to the proto-
col requirements. Exclusion criteria included: substantial
dementia (Folstein Mini-Mental State Examination score
of <24 of 30), active cardiopulmonary disease, acute
medical conditions not related to their head and neck can-
cer, such as acute flare-up of a joint condition or infec-
tion, refusal of a percutaneous endoscopic gastrostomy
(PEG) tube for supplementary nutrition if determined as
necessary by the treating physician, active treatment for
another cancer, exercising at a moderate intensity for
more than 150 minutes per week, or receiving physical
therapy at the time of enrollment. Age 40 was used as the
minimum given the relatively small number of younger
patients who present with head and neck cancer, espe-
cially at the Veterans Affairs (VA) treating facility.
Design and participant allocation
After institutional review board approved informed con-
sent, participants completed baseline assessments (see
below) and were then allocated to MPACT or control
groups after stratification by site, VA Ann Arbor Health
Care System or University of Michigan (UM). Then,
using a computerized algorithm, allocation to the MPACT
or control group was based on a minimization proce-
dure,30 which minimized the imbalance between the
MPACT and control groups in key potential confounding
variables, namely age, sex, and functional mobility (repre-
sented by comfortable gait speed).
Using intensity-modulated radiotherapy, patients were
treated with platinum-based concurrent CRT to a total
dose of 70 Gray. Concurrent CRT was delivered over 7
weeks to the primary tumor and bilateral neck. Chemo-
therapy was given weekly at the VA and every 3 weeks
at UM as tolerated by the patient. As per standard of
care, all participants were seen by the attending physician
and care team at least weekly. All participants met with a
dietician before the initiation of concurrent CRT, and
then again at the discretion of the attending physician if
the participant experienced greater than a 5% to 10%
decrease in BMI. Only 1 participant (a control) utilized a
PEG tube at baseline. All participants were reassessed at
weeks 7 and 14 (see below), the latter coinciding with a
standard follow-up visit with the attending physician and
care team.
Assessments
Key factors thought to change with concurrent CRT
and the MPACT intervention, including muscle strength,
functional mobility, self-reported QOL, and physician-
reported concurrent CRT toxicity, were assessed at base-
line, 7 weeks, and 14 weeks. In order to determine feasi-
bility for future studies and after initial accrual of
participants in both groups, a subsequent participant
recruited into the study group wore an actigraph for 7
days (objective physical activity assessment) and com-
pleted a 7-day diet journal (nutrition assessment). Asses-
sors were blinded to experimental group allocation.
Muscle strength. Elbow flexion and knee extension
strength (in Newton-meters) were assessed on the domi-
nant side using an isokinetic dynamometer and standard
positioning techniques (Biodex Medical Systems, Shirley,
NY). Grip strength (in kilograms) was assessed on the
right side using a hand dynamometer (Patterson Medical,
Bolingbrook, IL). The best of 2 trials was used as the out-
come unless the difference between the first and second
trials was >10%, in which case a third trial was done.
Functional mobility. These assessments followed standard
literature-based protocols. In addition to comfortable gait
speed (in meters/second) over a 6-minute distance, the
timed up and go (in seconds) was assessed as the time to
rise from a chair, walk 3 minutes away, and then return
to the chair and sit down31; the average of 2 trials was
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used for each outcome measure. For the 6-minute walk,
participants were told to cover as much distance (in feet)
as possible comfortably during a 6-minute hallway walk.
Self-reported quality of life. Participants completed the
Medical Outcomes Study (MOS) Short Form-36 (SF-36),
with analyses conducted of the summarized Physical and
Mental domains as well as 8 subcomponents, including
physical function, role-physical, role-mental, role-
emotional, vitality, mental health, social functioning,
pain, and general health.32 The 6-item MOS Sleep Prob-
lem Index (MOS-Sleep 6) was used to measure sleep ini-
tiation, maintenance, respiratory problems, adequacy, and
somnolence, with higher scores indicating more sleep dis-
turbance and worse sleep quality.33
Body mass index and lean body mass. Lean body mass (%)
was calculated using dual-energy X-ray absorptiometry,
as described previously.11
Self-reported physical activity. The Physical Activity Scale
for the Elderly (PASE) questionnaire assessed the fre-
quency of performing a variety of daily activities, includ-
ing muscle strength/endurance, housework, sports, tasks
involving standing or walking, and gardening. The PASE
score was calculated using the Washburn approach,34
with higher scores indicating higher activity level. Miss-
ing data was handed by proportionally reweighting the
remaining questions such that the sum of the weights was
conserved.
Objectively assessed physical activity. A subgroup of partic-
ipants wore an Actigraph GT3x1 accelerometer (Acti-
graph, Fort Walton Beach, FL) over the right hip for 7
consecutive days. Individuals were asked to remove the
device during sleep, bathing, and any other aquatic-
related activities. Actigraph data processing followed pre-
viously published standards.35 Non-wear time was defined
as >60 consecutive minutes of zero activity (counts/
minute), allowing for a tolerance spike of 2 minutes with
activity counts per minute between 0 and 100.35 To deter-
mine valid days of wear (>10 hours/day of wear time)
non-wear time was subtracted from 24 hours of data col-
lected.36 Total activity counts per minute during wear
time were classified into activity intensity levels using
previously established standards (0–99 counts 5 seden-
tary; 100–759 counts 5 light; 760–1951 5 lifestyle;
1952 5 moderate to vigorous activity.37,38 The propor-
tion of time spent in each activity intensity level was cal-
culated by dividing minutes of intensity-specific
movement by the total minutes of wear time. Further,
each time a minute of activity broke the <100 to the
>100 counts this activity was coded as a sedentary transi-
tion. For pilot purposes in the current article, we report
proportions of sedentary and lifestyle time, as well as
transitions in movement posture from sitting to standing.
Head and neck-specific quality of life. The 20-question Head
and Neck Quality of Life questionnaire was used to assess
disease-specific QOL across 4 domains: eating, communi-
cation, pain, emotion, as well as an additional single ques-
tion assessing “waking up frequently at night” because of
the patient’s head and neck condition.39 The analysis
included both the individual questions as well as the over-
all domain scores, which were transformed to a 0 to 100
scale, with higher scores indicating worse problems.
Barriers to exercise. In a “Barriers to Exercise” survey,
described previously,40 participants rated the frequency of
34 items that may have interfered with exercise in the
past 4 weeks on a 1 to 5 Likert scale. Sample items
included “lack of interest in exercise,” “lack of equi-
pment,” “fatigue,” “family responsibilities,” as well as
more treatment-specific items, including “difficulty
swallowing,” “decreased food intake,” “dry mouth or
throat,” and “need for tube feedings.” Higher scores indi-
cated increased frequency that the perceived barrier inter-
fered with exercise.
Smoking and alcohol use. Smoking habits were assessed
using the Fagerstr€om Nicotine Dependence Test, with
higher scores associated with greater dependency.41 Alco-
hol use was assessed using the Alcohol Use Disorders
Identification Test (AUDIT), with higher scores correlat-
ing with more problematic usage.42
Diet. A subgroup of participants was asked to keep 7-
day diet journals through week 7. These diet journals
were enumerated for servings of protein, dairy, grains,
fruits and vegetables, and meal replacements. Daily totals
in each category were calculated as was a “solid food”
summary score that added daily servings of grains, pro-
tein, fruits, and vegetables.
Concurrent chemoradiotherapy toxicity. Data on adverse
events were collected prospectively by the treating physi-
cian from the time of the initial concurrent CRT through
the end of the study. Adverse events were identified
based on descriptions and grading scales found in the
revised National Cancer Institute Common Toxicity Crite-
ria for Adverse Events.43 The proportion of patients expe-
riencing toxicities of interest, defined as grade 3 or
higher, blood count changes, mucositis, xerostomia, or
dermatitis were assessed.
Maintain physical activity during cancer treatment
intervention
The MPACT intervention was delivered at a clinical
research center by a trainer after concurrent CRT initia-
tion up to week 7 and then post-concurrent CRT at home,
with weekly trainer telephone calls from weeks 8 to 14.
The use of on-site plus follow-up telephonic support were
consistent with the most effective mode of delivery of
cancer rehabilitation programs.44 Controls received stand-
ard treatment, including active nutritional surveillance,
but were neither encouraged nor discouraged to exercise.
The initial 7-week MPACT program included initiation of
a functional resistance training and a home walking pro-
gram with concurrent CRT. The program followed Amer-
ican College of Sports Medicine prescription guidelines
for patients with cancer and included strengthening, cardi-
ovascular fitness, and physical activity components.
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Patients attended up to 3 sessions per week, lasting up to
1 hour as an eventual goal, including warmup, cool
down, and rest periods. The warmup included rhythmic
large muscle movements, such as marching and punching,
whereas the cool down included leg, shoulder, and arm
flexibility activities coupled with deep breathing. Exercise
intensity and duration was sometimes modified as the
effect of concurrent CRT intensified by the end of the
seventh week, and later slowly increased as the effect
waned. Participants were to perform the exercise program
described below at a moderate intensity, as defined by 11
to 13 on a 20-point rate of perceived exertion scale.
Functional resistance training. The functional resistance
training protocol was designed to minimize the loss of
muscle mass associated with head and neck cancer and
maintain and enhance physical activity levels during con-
current CRT. Upper body musculature were targeted
through whole body exercises to optimize the training
effect while reducing exercise fatigue and augmenting
lower extremity function. Emphasis was placed on the
development of a sustainable exercise habit, including safe
independent performance of the functional resistance train-
ing and exercises to include exercise progression and inte-
gration into daily activities. Exercises included chest press
in squat, wall push up, military press, side arm raises,
biceps curl, shoulder shrugs, and calf raises. Weights
included dumbbells and inserts into an ankle strap. Exer-
cise duration and intensity were customized to the individ-
ual. The goal was to perform three 8 to 12 repetition sets
of each functional resistance training exercise by the con-
clusion of the 7-week training period, to be customized in
terms of repetitions and weights based on concurrent CRT
side effects. Limited rest periods (eg, 2 minutes) were pro-
vided between sets to enhance the training effect.
Walking. For the cardiovascular and physical activity
component, participants were given a pedometer, and the
goal was to maintain step count based on the mean step
count of the previous training week. Multiple short dura-
tion continuous walking periods were recommended, such
as walking for 5 minutes 6 times throughout the day to
achieve a total walking time of 30 minutes. Participants
were also given information on optimal walking form,
injury prevention, program progression, and ways to
incorporate walking into daily life.
Home program. After the 7-week on-site training, MPACT
participants were asked to integrate safe exercise activities
into their own lifestyle through home activities. Partici-
pants were asked to perform their individualized functional
resistance and walking program solely off-site for the last
7 weeks of the study (weeks 8–14). Each participant’s
functional resistance in addition to walking and physical
activity program was customized based on: (1) personal
determinants (self-efficacy, benefits, and barriers); (2)
physical activity preferences; (3) available community
resources; and (4) health and environmental factors. The
goal was for participants to maintain their physical activity
for a minimum of 5 days a week and a minimum of
30 minutes per day, performed in bouts of 10 minutes
or more, at a moderate intensity (rate of perceived
exertion 5 11-13). The MPACT trainer made weekly tele-
phone calls to facilitate home program adherence through
week 14. The trainer addressed participant concerns and
barriers (such as weight loss, changes in medications, and
symptoms such as fatigue) and then used participant
strengths to identify tailored solutions to help each partici-
pant reach and/or maintain the exercise and physical activ-
ity goals. At week 11, when the participant returned for
follow-up to the radiation oncology clinic, the trainer met
with the participant to go over their individualized program
and review the exercise technique.
Statistical analysis
Baseline. Participant characteristics were compared at
baseline between MPACT and controls, using a 2-tailed t
test for continuous variables (including functional mobil-
ity and SF-36 measures), Fisher’s exact test for non-
ordered categorical variables, and Cochrane–Armitage
trend test for ordinal variables (eg, head and neck cancer-
specific QOL individual questions or barriers to exercise).
Baseline versus 7 and 14 weeks. Changes in measures
between baseline and week 7 or 14 were calculated for
each patient and compared between the MPACT and con-
trol treatment groups. Per the protocol, a 1-sided t test
was used to compare treatment groups with respect to
mean change from baseline to 7 or 14 weeks for continu-
ous outcomes. Mean change from baseline in Likert scale
variables (such as the head and neck cancer QOL and
Barriers to Exercise) was compared between treatment
groups using the Cochrane–Armitage trend tests. All
available data at each timepoint were used rather than
selecting only patients who completed all timepoints. Sta-
tistical significance was set at p < .05. All statistical
analyses were performed using R 3.0.1 statistical software
(http://www.r-project.org/).
RESULTS
Participant enrollment and attrition
Of the 27 consented participants, 7 did not complete
the program because they either withdrew, failed to meet
screening criteria, or were deemed noncompliant before
baseline testing and group allocation (see Figure 1). Ulti-
mately 20 patients were allocated, 11 to the MPACT
group and 9 to the control group. Seventeen patients (10
in the MPACT group and 7 in the control group) com-
pleted 14 weeks on-study. One MPACT participant dis-
continued all exercise sessions in the first week because
of difficulty with multiple appointments, but continued to
be assessed and was therefore included in the final analy-
sis. Of the 2 control withdrawals, 1 refused the control
group assignment and the second suffered a myocardial
infarction. Excluding the MPACT participant who discon-
tinued exercise in the first week, MPACT participants
completed an average of 15.2 sessions of a maximum 21
offered (72% attendance rate). The most common reason
for not attending a session was cancer-related or
treatment-related toxicity.
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Participant baseline characteristics
Table 1 shows the baseline characteristics for the 7
control and 11 MPACT participants who completed the
14-week testing. Eleven of these 18 were veterans. Mean
age was 57 years for both groups and all patients were
male except for a single UM female MPACT patient. The
majority of patients had oropharyngeal primary tumors,
including the base of the tongue and tonsil. There were
no significant differences between the 2 groups in chemo-
therapy, tumor stage, baseline PEG use, BMI, lean body
mass, alcohol use (AUDIT score), smoking (Fagerstr€om
score), or Karnofsky score. Baseline muscle strength and
functional mobility were similar between groups, except
for significantly higher knee extension strength in controls
versus MPACT (p 5 .04). There were no significant dif-
ferences at baseline in the SF-36 scores or subscores,
MOS Sleep-6, and physical activity based on the PASE
questionnaire. The baseline to 7 and 14 week changes in
assessment outcomes are presented in Table 2.
Muscle strength. Knee extension tended to be maintained
for all 14 weeks in MPACT versus a decline in controls
mostly by the seventh week, resulting in a significant
mean 14-week decrease of 4 Newton-meters (N-m) for
MPACT and 46 N-m for controls (p < .05; Figure 2).
There was no group difference in baseline to 7 or 14
week change in elbow flexion or grip strength.
Functional mobility. The 6-minute walk test showed a
trend toward less decline in MPACT than controls at 7
weeks (decrease of 71 feet in MPACT vs 166 feet in con-
trols). MPACT tended to improve at 14 weeks versus
baseline (by 60 feet), whereas controls decreased by 19
feet, although these differences were not statistically sig-
nificant (Figure 3). Comfortable gait speed in MPACT
and controls followed a trend at 7 and 14 weeks similar
to the 6-minute walk, but timed up and go did not.
Quality of life and sleep. QOL measured by SF-36 tended
to show less decline and even improvement in MPACT
versus controls when evaluating changes from baseline to
FIGURE 1. Study flow diagram.





(n 5 7) p value
Age, y 57 (7) 57 (7) .9
Institution
VA 7 4 1.0
UM 4 3
Tumor location
Larynx 1 0 1.0
Nasopharynx 1 0
Oropharynx 8 6
Unknown primary 1 1
Stage
Stage III 4 0 .1
Stage IV 7 7
Chemotherapy
Platinum only 9 5 1.0
Taxol 1 platinum 2 2
BMI 30 (5) 32 (3) .4
Percent lean body mass 62 (9) 62 (5) 1.0
Karnofsky performance score
<90 1 3 .2
90 8 3
NA 2 1
6-min walk distance, feet 1400 (243) 1530 (233) .3
Elbow flexion, N-m 54 (16) 60 (22) .6
Knee extension, N-m 154 (44) 224 (67) .04*
Grip strength, kg 42 (8) 45 (9) .5
Timed up and go, sec 8 (3) 8 (1) .6
Gait speed, m/s 1.3 (0.2) 1.5 (0.2) .8
MOS sleep score 34 (19) 41 (20) .5
PASE 147 (90) 150 (116) 1.0
SF-36 64 (22) 56 (22) .5
Physical 67 (20) 56 (23) .3
Mental 61 (29) 60 (26) .9
Physical function 82 (19) 69 (26) .3
Role-physical 50 (39) 36 (45) .5
Role-emotional 64 (46) 57 (54) .8
Vitality 58 (23) 54 (21) .7
Mental health 62 (27) 67 (28) .7
Social functioning 60 (33) 61 (38) 1.0
Pain 50 (31) 31 (8) .1
General health 58 (18) 55 (17) .8
AUDIT 4 (4) 3 (4) 1.0
Fagerstr€om, smoking 2 (4) 3 (4) .9
Barriers to exercise
Lack of interest 2.6 (1.3) 2.8 (1.8) .7
Exercise is boring 2.2 (1.3) 2.1 (1.7) 1.0
Hand neck cancer-related QOL
Domain: emotion 47 (28) 38 (28) .5
Domain: communication 23 (23) 44 (34) .2
Domain: eating 23 (20) 38 (35) .3
Domain: pain 37 (28) 49 (24) .3
Abbreviations: MPACT, maintain physical activity during cancer treatment; VA, Veterans
Affairs; UM, University of Michigan; BMI, body mass index; NA, not applicable; N-m, Newton-
meter; m/s, meters/second; MOS, Medical Outcomes Study; PASE, Physical Activity Scale for
the Elderly; SF-36, Short Form Health Survey; AUDIT, Alcohol Use Disorders Identification
Test; QOL, quality of life.
Numbers represent the number of patients (n) or mean value (SD). All 18 patients (everyone
who began and did not subsequently withdraw from the study) are included, regardless of
whether or not they completed all sessions
* p < .05.
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7 and 14 weeks. In MPACT versus controls and com-
pared to baseline, overall SF-36 scores tended to decline
less at 7 weeks (219 vs 224) and improved at 14 weeks
(14 vs 26; Figure 4A). The SF-36 physical summary
measure declined similarly in both groups at 7 weeks
but the MPACT group returned to baseline at 14 weeks
compared to a continued deficit in controls (23). The
SF-36 mental summary score declined less in MPACT
than controls by 7 weeks (212 vs 226) and improved in
MPACT versus continued decline in controls (19 vs
29). Of the other subscales evaluated that showed group
differences, the SF-36 vitality subscale measuring energy
and fatigue showed similar trends at 7 weeks (219 for
MPACT and 233 for controls; p < .05) and 14 weeks
(17 vs 29; Figure 4B). In addition, the SF-36 mental
health subscale showed significant improvement in
MPACT versus decline in controls at 7 weeks (13 vs
216; p < .05) and 14 weeks (115 vs 21; p < .05; Fig-
ure 4C). The MOS Sleep Index tended to show continu-
ous improvement in sleep disturbance in the MPACT
group versus controls at weeks 7 (25 vs 18) and 14
(214 vs 21).
TABLE 2. Mean (SE) change in assessment outcome at weeks 7 and 14.
Measure










Knee extension strength, N-m 1 (11) 236 (16)* 24 (7) 246 (14)†
6-min walk distance, feet 271 (36) 2166 (93) 60 (40) 219 (89)
Comfortable gait speed, m/s 20.08 (0.04) 20.14 (0.09) 0.02 (0.04) 20.05 (0.06)
Timed up and go (s) 0.7 (0.8) 20.07 (0.7) 20.7 (0.6) 20.2 (0.6)
Quality of life and sleep
Overall SF-36 219 (5) 224 (5) 4 (4) 26 (8)
SF-36 physical summary 224 (6) 222 (8) 1 (4) 23 (8)
SF-36 mental summary 212 (7) 226 (6) 9 (4) 29 (12)
SF-36 subscale: vitality 219 (7) 233 (3)* 7 (5) 29 (10)
SF-36 subscale: mental health 3 (4) 216 (7)* 15 (4) 21 (6)†
MOS sleep index 25 (5) 8 (6) 214 (5) 21 (11)
BMI and lean body mass
BMI 22.9 (0.6) 23 (0.5) 23.9 (0.7) 24.6 (0.6)
Lean body mass, percent 0.2 (0.5) 1.0 (0.7) 4.7 (1.5) 4.0 (0.9)
Self-reported physical activity
PASE 265 (24) 296 (35) 42 (18) 210 (31)
Objective physical activity (n 5 4) (n 5 3) (n 5 4) (n 5 3)
Proportion of lifestyle min 20.03 (0.01) 20.07 (0.03) 0.00 (0.01) 20.03 (0.01)
Proportion of sedentary min 0.04 (0.02) 0.08 (0.02) 20.02 (0.02) 0.06 (0.03)
No. of sit-to-stand transitions 11.5 (7.9) 22.7 (5.2) 6.7 (8.9) 1.8 (2.1)
Abbreviations: MPACT, maintain physical activity during cancer treatment; N-m, Newton-meter; m/s, meters/second; SF-36, Short Form Health Survey; MOS, Medical Outcomes Study; BMI, body
mass index; PASE, Physical Activity Scale for the Elderly.
* Refers to p < .05 when comparing MPACT vs controls from baseline to 7-weeks.
† Refers to p < .05 when comparing MPACT vs controls from baseline to 14-weeks.
FIGURE 2. Group mean (SE) change in knee extension strength (in
Newton-meters) at 7 and 14 weeks (maintain physical activity
during cancer treatment [MPACT] 5 11; controls 5 7). *p < .05.
FIGURE 3. Group mean (SE) change in the 6-minute walk distance
(in feet) at 7 and 14 weeks (maintain physical activity during can-
cer treatment [MPACT] 5 11; controls 5 7).
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Head and neck-specific quality of life. Notable changes in
head and neck-specific QOL survey items were in the
same direction. When we examined the 21 items individ-
ually, one statistically significant finding was in emo-
tional problems: MPACT participants reported fewer
problems than controls when comparing 7 weeks to base-
line (p < .05). No differences between the MPACT and
the control groups were found in the change in overall
domain scores. Baseline domain scores were higher than
previously described, largely driven by mean baseline
scores for the VA patients (emotion, 55; communication,
42; eating, 38; and pain, 52) that were significantly higher
for every domain than for the UM patients (emotion, 24;
communication, 14; eating, 13; and pain, 26), consistent
with prior results.45–47
Body mass index and lean body mass. BMI declined by an
average of 3 points by week 7 and 4 to 5 points by week
14 in both the MPACT and control groups. Lean body
mass tended to improve slightly by 7 weeks in MPACT
(0.2%) and controls (1%) and more substantially by week
14 (5% and 4%, respectively).
Self-reported and objectively assessed physical activity
Using the PASE, the decline in self-reported physical
activity was more attenuated at 7 weeks and tended to
show greater improvement at 14 weeks compared to base-
line in MPACT versus controls (7 weeks, 265 vs 296;
14 weeks, 142 vs 210 points, respectively). Objective
physical activity monitoring via actigraph assessment was
available on a subsample (4 MPACT and 3 controls) of
participants. MPACT versus controls decreased less in the
proportion of time spent in lifestyle activity by week 7
(3% vs 7% reduction, respectively), with MPACT return-
ing back to baseline levels by week 14. The proportion of
time spent in sedentary behavior increased less in the
MPACT group versus controls by week 7 (4% vs 8%
increase, respectively), and actually decreased overall by
2% in the MPACT group by week 14 (Figure 5). Postural
transitions of sit to stand increased by 10 in the MPACT
group by week 7, with some retention of this increase
through week 14, compared to essentially no change in
sit to stand transitions in the controls.
Barriers to exercise. Of the 34 barriers assessed, most
showed no differences in change between groups, with 2
notable exceptions. Lack of interest in exercise as a bar-
rier tended to be unchanged at 7 weeks in MPACT but
was significantly more of a barrier in the controls (0 vs
11.6; p < .05). Exercise being classified as boring was
FIGURE 4. Group mean (SE) change in Short Form Health Survey
(SF-36) scores at 7 and 14 weeks. (A) Total SF-36 score; (B) vitality
subscore; and (C) mental health subscore (maintain physical activity
during cancer treatment [MPACT] 5 11; controls 5 7). *p < .05.
FIGURE 5. Group mean (SE) change in proportion of time spent in
sedentary behavior, as measured by actigraphy, at 7 and 14
weeks (maintain physical activity during cancer treatment
[MPACT] 5 4; controls 5 3).
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also more of a barrier at 7 weeks in the controls than in
the MPACT group (10.8 vs 20.6; p < .05).
Diet. Complete diet journals were available on a sub-
sample (5 MPACT and 3 controls). Fruit and vegetable
intakes at study start were about 2 to 3 servings/day, well
below the United States Department of Agriculture
(USDA) recommendation of 7 to 11/day, and dropped
greatly as use of meal replacements increased. The
decrease in fruit and vegetable consumption was less pro-
nounced in the MPACT group and tended to be better
maintained versus the control group, as seen in Table 3.
There also was a trend for MPACT to return to solid
foods more quickly than controls at week 7 (Figure 6).
Concurrent chemoradiotherapy toxicity. Reports of concur-
rent CRT toxicity over the 14-week period did not differ
between groups.
DISCUSSION
In this pilot controlled trial of patients with head and
neck cancer, we demonstrated the feasibility of a func-
tional resistance and walking exercise intervention
(MPACT) provided during 7 weeks of concurrent CRT
and during 7 weeks of follow-up. Once enrolled, MPACT
participants, despite the concurrent CRT, completed 72%
of the on-site exercise sessions. Ten of 11 of the MPACT
participants (91%) completed the full 14-week program,
with the 11th participant discontinuing training at week 1.
As hypothesized, compared with controls and in evalu-
ating changes from baseline to 7 and 14 weeks, MPACT
participants tended to exhibit less concurrent CRT-
induced decline and even some improvement. These
trends were found in nearly all measured domains,
namely in muscle strength, functional mobility, QOL,
sleep disturbance, head and neck-specific QOL, self-
reported and objectively assessed physical activity, bar-
riers to exercise, and diet. Despite the small sample size,
statistically significant changes in MPACT versus controls
were noted in knee strength, mental health and head and
neck QOL, and barriers to exercise.
Trends in changes favoring MPACT over controls in
muscle strength and functional mobility occurred espe-
cially in knee extension strength and 6-minute walk dis-
tance. Despite the inclusion of whole body functional
exercises, the MPACT focus on upright exercise likely
favored lower extremity strength, whereas the home pro-
gram focus on increased walk time favored longer walk
measures, such as the 6-minute walk (vs shorter walk
measures such as gait speed). For the 6-minute walk,
clinically meaningful changes in older adults have been
proposed at 2 levels, small (20 minutes, 66 feet) and sub-
stantial (50 minutes, 164 feet).48 Thus, in the present
study, MPACT participants exhibited a small meaningful
decline at 7 weeks (274 feet) and a small meaningful
improvement at 14 weeks (167 feet); controls exhibited
substantial decline at 7 weeks (2166 feet) and minimal
change (23 feet) at 14 weeks.
Other studies during head and neck cancer treatment
find analogous but sometimes conflicting training-induced
changes in strength and functional mobility. Samuel
et al49 utilized a combined 6-week resistance training and
walking program during concurrent CRT and found simi-
lar results, with improvement in the 6-minute walk at 6
weeks of a median of 43 minutes versus a decline in the
control group of a median of 96 minutes. In a small 12-
week pilot of resistance-band training with a design anal-
ogous to the present study (6 weeks on-site during con-
current CRT and 6 weeks home-based after concurrent
CRT), the main tendency for resistance training (n 5 5)
versus controls (n 5 8) was to reduce the average time to
rise from a chair, but there was a decline in back/leg
extensor strength.50
Studies conducted posttreatment for cancer utilized var-
ious interventions to improve muscle strength and func-
tional mobility. Physiotherapy-guided training in a single
group 8-week trial improved the 6-minute walk distance51
compared to self-selected physical activity controls,
whereas 12 weeks of resistance training improved lean
body mass and strength but not functional mobility.52 No
differences in BMI or lean body mass were seen in the
present study between the control and intervention
groups, possibly because the resistance training load was
TABLE 3. Mean (SE) dietary journal assessments in the maintain physical activity during cancer treatment group (n 5 5) and the control group (n 5 3).
Measure
Wk 1 Wk 4 Wk 6 Wk 7
MPACT Control MPACT Control MPACT Control MPACT Control
Fruit and vegetable servings 1.8 (0.6) 2.9 (0.6) 1.1 (0.4) 1.7 (0.5) 1.2 (0.6) 0.7 (0.5) 1.4 (0.8) 0.5 (0.3)
Solid food servings 6.3 (1.0) 7.2 (1.3) 3.8 (1.5) 4.5 (0.4) 2.6 (1.2) 1.7 (0.9) 3.6 (1.7) 1.2 (0.7)
Meal replacements 1.1 (0.8) 0.4 (0.3) 3.3 (1.6) 1.4 (0.6) 3.4 (1.4) 3.5 (1.4) 2.5 (0.8) 3.3 (1.3)
Abbreviation: MPACT, maintain physical activity during cancer treatment.
FIGURE 6. Group mean (SE) solid food servings per day at 1, 4, 6,
and 7 weeks (maintain physical activity during cancer treatment
[MPACT] 5 5, control 5 3).
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more functional and not at a high load (such as 80% of 1
repetition maxima). In summary, exercise programs pro-
viding both resistance and walking training might
improve muscle strength and functional mobility in
patients with head and neck cancer both during and after
concurrent CRT, with the suggestion that there is likely
to be a degree of training specificity necessary (ie, walk-
ing training to improve walking). Further controlled stud-
ies are needed with more prolonged follow-up50 to
evaluate how well these changes are maintained.
Tendencies for less decline and even improvement
favoring MPACT over controls were noted in QOL meas-
ures, both general (particularly SF-36 physical summary,
mental summary, and vitality/fatigue scales) and head and
neck cancer-specific (particularly emotional problems).
Statistically significant changes favoring MPACT were
found in the SF-36 mental health scale, waking at night,
and lack of interest in exercise. Using the proposed Reli-
able Change Index (RCI; the change between pretreat-
ment and post-treatment scores that would be statistically
and clinically reliable53), these differences in SF-36
change from baseline between groups are reliable at 14
weeks for the physical summary score (RCI 5 7), and at
both 7 and 14 weeks for the mental summary score (RCI
5 10), the vitality subscore (RCI 5 10), and the mental
health subscore (RCI 5 11). Other studies also have
found QOL-related improvement with exercise programs
in head and neck cancer participants, and there was often
a greater effect in the mental health component. In the
study by Samuel et al,49 the intervention group median
scores were stable (SF-36 physical component) or slightly
improved (SF-36 mental component), whereas the con-
trols decreased in both, most strikingly on the mental
component. Using the Functional Assessment of Cancer
Therapy (FACT) scales, Rogers et al54 found tendencies
favoring intervention over control for FACT-G (general),
physical well-being, emotional well-being, and functional
well-being, as well as a blunting of increases in the
fatigue subscale, with no changes for head and neck-
specific scores (FACT-H&N). This blunting of the fatigue
subscale and, in the present study, the SF-36 vitality/
fatigue scale, is consistent with literature showing that
exercise mitigates cancer-related fatigue.44 Note that
improvement in QOL may have been facilitated by the
telephone trainer support contact; multidisciplinary reha-
bilitation programs that contain a psychosocial as well as
a physical component have been shown to improve SF-36
scores in cancer survivors in a large meta-analysis.55
Sleep disorders are another significant contributor to
fatigue and decreased QOL in patients with cancer,56 and
sleep quality is poorer in patients with head and neck
cancer compared to a healthy population.57 In the present
study, compared to controls, the MPACT group showed
continuous improvement in this MOS Sleep-6. Factors in
multiple domains likely influence sleep quality. Predictors
of poor sleep quality among patients with head and neck
cancer, both at baseline and at 1-year follow-up include
pain, xerostomia, depression, the presence of a tracheos-
tomy tube, comorbidities, and younger age,57 none of
which seemed to differ between the present study groups.
Obstructive sleep apnea has also been recently proposed
as a contributor to sleep disorders and fatigue in patients
with head and neck cancer.58 Previous work suggests that
decreased sleep is an independent predictor of increased
inflammatory marker levels, specifically interleukin-6.59
Elevated inflammatory markers are associated with cancer
cachexia, muscle wasting, and radiation treatment51,52; on
the other hand, exercise training may decrease inflamma-
tion as well as improve sleep in healthy older adults.60
The impact of exercise training on sleep and inflamma-
tory markers in patients with head and neck cancer (and
patients with cancer in general) undergoing definitive
treatment has not been carefully studied and may be an
important new area of research.
Compared with controls, the decline in self-reported
physical activity tended to be more attenuated in the
MPACT group at 7 weeks and improved more by week
14. As noted in a previous review, physical activity (and
exercise) is compromised in patients with head and neck
cancer.8 Enjoyment of physical activity, task efficacy
(confidence), and any alcohol use are positively correlated
with physical activity, whereas symptom index, comor-
bidity score, and perceived barriers are negatively corre-
lated with physical activity.40 There was little difference
in reported barriers to exercise, although the MPACT
group reported no change in lack of interest, whereas the
controls increased in lack of interest. One possible con-
tributor to the continued interest and lack of difference in
barriers may have been the support of the trainers, both
on-site and in telephone follow-up. Providing feedback
and support, and promoting knowledge and skills have
been identified as key contributors to adherence in breast
cancer strength training participants.61 Taken along with
the improvement in SF-36 mental health measures, future
studies utilizing MPACT will need to explore the impor-
tance of cognitive-behavioral support and outcomes.
In order to determine feasibility for future studies, both
actigraphy and diet were analyzed in small subsets, and
seem to be feasible and follow the trends noted above.
Actigraphy provided important objective trends favoring
MPACT in maintaining lifestyle physical activity and
avoiding more sedentary activity, and in showing an
increase in posture changes from sitting to standing.
These outcomes help to verify the attainment of physical
activity goals based on American College of Sports Medi-
cine guidelines and provide a more objective outcome for
use in future intervention studies. In terms of diet, the
MPACT group may have maintained their nutrition better
and returned to eating solid foods faster than the controls.
This could reflect better physical function and recovery
from treatment, but this observation as well as the influ-
ence of diet on the other outcomes, have to be confirmed
in larger studies.
One important study limitation was the small sample
size, which limited the statistical power, but the assess-
ment and intervention paradigm are feasible. An addi-
tional limitation of the study was that HPV status was not
available for every patient. Although we doubt that this
would have changed the results of our study, it is possible
that given the better prognosis of HPV-positive patients
they are even more likely to benefit from a physical
activity program. The lack of a detailed record of adher-
ence to the home program was an additional limitation.
Future studies supplementing self-reported physical
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activity with objective measures such as actigraphy can
help verify the extent of actual physical activity per-
formed, both as a check for adherence and as an objective
outcome measure. Strengths include the use of a control
group, measures validated for use in patients with cancer,
an intervention that began with the start of cancer treat-
ment and continued in early posttreatment follow-up, an
intervention oriented to functional strength, walking, and
physical activity, and use of both an on-site and home-
based intervention.
In summary, the MPACT functional resistance and
walking exercise intervention for patients with head and
neck cancer, both during concurrent CRT and afterward,
seems feasible. The findings of attenuation in decline dur-
ing concurrent CRT as well as improvements up through
14 weeks in the MPACT versus control groups suggest
efficacy. Improvements tended to occur not just in physi-
cal but also in mental/behavioral outcomes, suggesting a
broader effect of the program. Data from this study can
be used to guide a more extensive intervention with
longer-term follow-up to demonstrate long-term mainte-
nance and enhancement of post-concurrent CRT recovery.
The results of this study can guide care for patients with
cancer treated with concurrent CRT and help address the
long-term physical and psychosocial rehabilitation needs
of cancer survivors.
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